VolitionRx Files 10‑Q/A to Add Omitted Exhibits; No Change to Financials

VolitionRx Limited (VNRX) - NYSE American

Quick summary
This is an Amendment No. 1 to VolitionRx's Form 10‑Q for the quarter ended June 30, 2025 (originally filed Aug 14, 2025). The amendment was filed to add omitted exhibits (not to change financial results). It does not include or revise the company's financial statements or the income statement.

Key facts & statistics
- Amendment filed: August 15, 2025 (original Form 10‑Q filed August 14, 2025).
- Purpose: add Exhibits 5.1 and 10.2 that were omitted from the original 10‑Q.
- Shares outstanding (as of Aug 7, 2025): 107,595,421.
- Commission File No.: 001-36833.
- New/furnished exhibits added in this amendment: Exhibits 5.1 (legal opinion), 10.2 (Amendment No. 1 to Capital On Demand™ Sales Agreement), 31.3 and 31.4 (Certifications).
- Other material financing/transaction exhibits already in filings: Capital On Demand sales agreement (4/22/2025), Securities Purchase Agreement (May 15, 2025, as amended), Senior Secured Convertible Promissory Note and related warrants/security agreements (May 15, 2025).

What's happening inside the company
- Administrative/compliance action: management corrected an omission by filing this 10‑Q/A and added missing exhibits and updated Sarbanes‑Oxley Section 302 certifications.
- Financing activity: the company has active financing arrangements in filings (capital on demand agreement, securities purchase agreement, senior secured convertible note and warrants, pledge/guaranty agreements), indicating ongoing capital-raising efforts and secured creditor relationships.
- No change to previously reported financial position or results: the amendment explicitly states it does not modify or update the financial statements or results of operations disclosed in the original Form 10‑Q.

Income statement - positive aspects
- No restatement disclosed: the amendment does not alter the company's reported income statement, which avoids an accounting restatement flag.
- Ongoing regulatory compliance steps taken: including omitted exhibits and updated certifications improves disclosure completeness and governance signaling.

Income statement - negative / risk aspects
- No new income statement detail provided in the amendment - investors get no incremental clarity on revenue, margins or trends from this filing.
- Financing structure implies potential future dilution and financing costs: the existence of a senior secured convertible promissory note, warrants and securities purchase agreements suggests convertible debt and equity dilution risk, and likely ongoing negative operating cash flow requiring external capital.
- Secured/pledged assets and guaranties noted in exhibits create creditor priority that could affect equity holders if balance-sheet stress continues.
- Company remains a non‑accelerated, smaller reporting company - disclosure may be more limited than larger peers.

Takeaway
This filing is a housekeeping amendment to restore omitted exhibits and supply required certifications - not a financial update. The corporate picture shows active capital-raising and secured financing arrangements, which signal dependence on external funding and possible dilution risk. For any meaningful assessment of profitability or trend in the income statement, refer to the original Form 10‑Q and subsequent financial filings (this amendment does not change those numbers).

Read the full amendment/exhibits in the SEC filing history and the original 10‑Q for financial details before making investment decisions.